share_log

Credit Suisse Maintains Outperform on Fulgent Genetics, Lowers Price Target to $45

Benzinga ·  Mar 2, 2023 06:43

Credit Suisse analyst Dan Leonard maintains Fulgent Genetics (NASDAQ:FLGT) with a Outperform and lowers the price target from $50 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment